Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Target Raised at Royal Bank Of Canada

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by stock analysts at Royal Bank Of Canada from $296.00 to $305.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada‘s price objective would indicate a potential upside of 32.42% from the company’s previous close.

Several other equities analysts have also commented on the stock. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Barclays lifted their price target on shares of Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an “overweight” rating in a report on Thursday, September 10th. Citigroup began coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, September 30th. They issued a “buy” rating and a $325.00 price target on the stock. Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $322.00 to $314.00 and set an “overweight” rating for the company in a research note on Wednesday, October 21st. Finally, Stifel Nicolaus set a $275.00 price objective on Jazz Pharmaceuticals in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $292.70.

Jazz Pharmaceuticals Trading Up 7.4%

JAZZ traded up $15.88 during midday trading on Tuesday, hitting $230.32. The company’s stock had a trading volume of 215,950 shares, compared to its average volume of 927,309. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The firm has a market cap of $14.95 billion, a P/E ratio of 15.70, a PEG ratio of 0.41 and a beta of 0.38. The firm has a 50-day moving average price of $231.16 and a two-hundred day moving average price of $216.50. Jazz Pharmaceuticals has a 52-week low of $128.80 and a 52-week high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts’ consensus estimates of ($4.05) by $0.17. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $8.13 EPS. On average, research analysts anticipate that Jazz Pharmaceuticals will post 10.87 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the sale, the executive vice president owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. This represents a 2.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the transaction, the executive vice president owned 65,686 shares in the company, valued at $16,401,794.20. The trade was a 53.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 94,121 shares of company stock valued at $23,337,922. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. USA Financial Formulas acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter worth $25,000. Pension & Wealth Management Advisors Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $32,000. Ameritas Advisory Services LLC acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $47,000. Westpac Banking Corp acquired a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at $51,000. Finally, Root Financial Partners LLC boosted its position in Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 89 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported third-quarter revenue of approximately $1.24 billion, up 10.4% year over year and above the roughly $1.21 billion analyst estimate. Adjusted loss of $3.88 per share was narrower than the consensus loss of $4.05. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 revenue outlook to approximately $4.8 billion-$4.9 billion, above the $4.7 billion-$4.73 billion consensus range. The increased forecast signals continued confidence in commercial execution. Jazz 2026 Revenue Guidance
• Positive Sentiment: Ziihera launched in first-line HER2-positive metastatic gastric and esophageal cancer, while management identified potential peak sales of $3 billion-$5 billion. Xywav revenue also grew 12%, with 425 net patient additions during the quarter. Ziihera Launch and Guidance
• Neutral Sentiment: Jazz completed its Actio acquisition, adding the ABS-1230 epilepsy candidate to its rare-neurology portfolio. The company will also present Phase 3 ACTION and Phase 2 brain-cancer research at the Society for Neuro-Oncology meeting, offering potential future catalysts but no immediate revenue impact. Jazz Neuro-Oncology Research
• Negative Sentiment: The quarter’s loss contrasts sharply with $8.13 per-share earnings a year earlier. Investors may also remain cautious about decelerating growth and acquisition-related charges associated with Actio, leaving the stock at a crossroads despite the improved outlook. Jazz Earnings and Guidance Analysis

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.